Startup

Aleva Neurotherapeutics

Description

Aleva Neurotherapeutics, a spin-off of the Swiss Federal Institute of Technology in Lausanne, pioneers Directional Deep Brain Stimulation (DBS) technology for treating neurological and psychiatric diseases. Their system, featuring a directional lead with 24 contacts and a Multiple Independent Current Control (MICC) generator, offers the highest precision in directional stimulation. By focusing on improving manufacturing methods and utilizing sophisticated technologies, Aleva aims to enhance the existing DBS treatment for patients suffering from Neurological Disorders. With 13 patent families and 90 granted patents in the field, Aleva is committed to developing technologies that eliminate surgical failures and non-responder patients. The company collaborates closely with leading neurological clinics in Europe to provide personalized support and improve the lives of patients.

About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.